Advancing kidney and rare disease drug development with real-world data

Accelerate kidney and rare disease drug development The RenasightIQ™ clinicogenomic database empowers every stage of the drug development lifecycle with genetic, variant, and longitudinal clinical and claim data for over 215,000 chronic kidney disease (CKD) patients. https://www.natera.com/organ-health/renasight-genetic-testing/pharma-research/?utm_campaign=1637925676&utm_medium=banner&_hsenc=p2ANqtz--1KC4dlAiWupeeMWt2nXiFmSEDi2_t51qX4Z-NzbVunbiVDXVZwDhBfcrg4IlfKbZQb8vp3gggQIUE3OL3oE9pChAkWQ&_hsmi=418765841&utm_source=ddn A clinicogenomic database combining genetic and clinical data from more than 215,000 patients with chronic kidney disease is empowering every stage of the drug development lifecycle.